Guidance from World Health Organization (WHO), United Nations Office on Drugs and Crime (UNODC) and Joint United Nations Programme on HIV/AIDS (UNAIDS) suggests that reversing an HIV epidemic requires 60% of all people who inject drugs (PWID) to be reached regularly by a needle syringe program (NSP), and that 40% of all opiate users be enrolled in opioid substitution therapy (OST).
Governments of Central and East Europe and Central Asia (CEECA) provide less than 15% of harm reduction funding needed in the region, which indicates region’s strong dependency on international donors who support both NSP and OST. At the same time, many of the countries in the EECA region are becoming ineligible to receive donor funding due to increasing GNP per capita level. There are no more countries in CEECA that are classified as low-income – the funding priority for key donors such as the Global Fund to Fight AIDS, Tuberculosis and Malaria.
Epidemics among PWID cannot be reversed without greater and sustained state funding of harm reduction. Investments are needed to improve service quality and coverage level of both NSP and OST. Governments and other domestic sources have responsibility for meeting these investment needs which is one of the advocacy priorities for the Eurasian Harm Reduction Association.